While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

One of the most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as strategically sound for ...

Notably, there has been speculation about a potential acquisition of SpringWorks by Merck (NSE:PROR) KGaA. Analysts view this potential acquisition as strategically sound for several reasons: 1. There ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...